Lilly, ThyssenKrupp, Adidas, AMD: Intellectual Property
This article is for subscribers only.
May 17 (Bloomberg) -- Canada’s Supreme Court dismissed EliLilly & Co.’s request to appeal a federal court decision thatinvalidated its Canadian patent for schizophrenia drug Zyprexa.
The country’s highest court said in a statement yesterdayit decided not to look at the case after hearing from partiesinvolved in the matter earlier this week. A Federal Court in2011 ruled the patent was invalid because it didn’t meet“utility” requirements.